Large-cap pharmaceuticals
LLY vs AZN
Eli Lilly and Company (diabetes, obesity, and oncology medicines) against AstraZeneca PLC (oncology and biopharmaceuticals) — valuation, growth, and quality from SEC-filed fundamentals and delayed quotes.
| Metric | LLY | AZN |
|---|---|---|
| Price | $1,179.11 | $168.90 |
| Market cap | $1.05T | $290.1B |
| P/ETTM | 51.4 | — |
| Forward P/ENTM est. | 28.0 | — |
| EV / EBITDATTM | 30.1 | — |
| PEG | 1.6 | — |
| FCF yield | — | — |
| RevenueFY 2025 | $65 | — |
| Revenue growth, 3y CAGRFY 2025 | 31.7% | — |
| Net marginFY 2025 | 31.7% | — |
| Piotroski F-scoreFY 2025 | 7/9 | — |
| Altman Z-scoreFY 2025 | 8.4 | — |
| 52-week range | $623.78 – $1,249.45 | $137.22 – $212.71 |
Quotes as of 2026-07-18 21:23 UTC · delayed. Fundamentals from SEC EDGAR filings, basis labeled per column. Missing values shown as em-dashes, never estimated.
More in large-cap pharmaceuticals
ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comFundamentals parsed first-hand from SEC EDGAR filings · Quotes delayed · as of 2026-07-18 21:23 UTC
Run the full LLY vs AZN workup in the terminal
Ten years of statements, DCF fair value, verdict scoring, and side-by-side charting — free account, no card.
For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.